Interim analysis of an RCT in 92 patients with asymptomatic biochemical relapse of multiple myeloma: daratumumab vs observation gave median EFS 28.9 vs 4.0 months (HR 0.25); 24-month overall survival 100% vs 70.5%.
RCTn = 92
Jamroziak et al. Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma